Characterization of human mesenchymal stem cells from multiple donors and the implications for large scale bioprocess development

Biochemical Engineering Journal

Volumn 108, Issue , 2016, Pages 14-23

  Heathman, Thomas R J ^a   Rafiq, Qasim A ^a,b   Chan, Alexander K C ^a   Coopman, Karen ^a   Nienow, Alvin W ^a,c   Kara, Bo ^d   Hewitt, Christopher J ^a,b  

^a LOUGHBOROUGH UNIVERSITY   (United Kingdom)

^b ASTON UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Fujifilm Diosynth Biotechnologies   (United Kingdom)

Author keywords

Biomedical; Bioprocess design; Characterization; Human mesenchymal stem cells; Scale up; Tissue cell culture

Indexed keywords

BIOMATERIALS; CELL CULTURE; CHARACTERIZATION; CYTOLOGY; MANUFACTURE; STEM CELLS; TISSUE; TISSUE CULTURE;

BIOMEDICAL; BIOPROCESS DESIGN; BIOPROCESS DEVELOPMENT; COLONY FORMING EFFICIENCIES; HUMAN MESENCHYMAL STEM CELLS; MANUFACTURING PROCESS; MANUFACTURING PRODUCTS; SCALE-UP;

CELLS;

AMMONIA; GLUCOSE; INTERLEUKIN 6; LACTIC ACID;

ARTICLE; BIOPROCESS; BONE MARROW DERIVED MESENCHYMAL STEM CELL; CELL CULTURE; GLUCOSE INTAKE; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL;

EID: 84959376826     PISSN: 1369703X     EISSN: 1873295X     Source Type: Journal    
DOI: 10.1016/j.bej.2015.06.018     Document Type: Article

References (28)

1. Heathman T.R.J., Nienow A.W., McCall M.J., Coopman K., Kara B., Hewitt C.J. The translation of cell-based therapies: clinical landscape and manufacturing challenges. Regener. Med. 2015, 10:49-64.
2. Rafiq Q.A., Hewitt C.J. Cell therapies: why scale matters. Pharm. Bioprocess. 2015, 3:97-99.
3. Hourd P., Chandra A., Alvey D., Ginty P., McCall M., Ratcliffe E., Rayment E., Williams D.J. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products. Regener. Med. 2014, 9:799-815.
4. Rafiq Q.A., Heathman T.R.J., Coopman K., Nienow A.W., Hewitt C.J. Chapter 10. Scale-up of Stem Cell Manufacture for Cell Therapy Needs in Bioreactors: Design, Operation and Novel Applications 2015, Wiley VCH.
5. Rafiq Q.A., Coopman K., Hewitt C.J. Scale-up of human mesenchymal stem cell culture: current technologies and future challenges. Curr. Opin. Chem. Eng. 2013, 2:8-16.
6. Jung S., Panchalingam K.M., Rosenberg L., Behie L.A. Ex vivo expansion of human mesenchymal stem cells in defined serum-free media. Stem Cells Int. 2012, 2012:21.
7. Rafiq Q.A., Brosnan K.M., Coopman K., Nienow A.W., Hewitt C.J. Culture of human mesenchymal stem cells on microcarriers in a 5 l stirred-tank bioreactor. Biotechnol. Lett. 2013, 35:1233-1245.
8. Heathman T.R.J., Glyn V.A.M., Picken A., Rafiq Q.A., Coopman K., Nienow A.W., Kara B., Hewitt C.J. Expansion, harvest and cryopreservation of human mesenchymal stem cells in a serum-free microcarrier process. Biotechnol. Bioeng. 2015, 112:1696-1707.
9. Chan A.K., Heathman T.R., Coopman K., Hewitt C.J. Multiparameter flow cytometry for the characterisation of extracellular markers on human mesenchymal stem cells. Biotechnol. Lett. 2014, 36:731-741.
10. Naing M.W., Gibson D.A., Hourd P., Gomez S.G., Horton R.B., Segal J., Williams D.J. Improving umbilical cord blood processing to increase total nucleated cell count yield and reduce cord input wastage by managing the consequences of input variation. Cytotherapy 2015, 17:58-67.
11. Rafiq Q.A., Coopman K., Nienow A.W., Hewitt C.J. A quantitative approach for understanding small-scale human mesenchymal stem cell culture - implications for large-scale bioprocess development. Biotechnol. J. 2013, 8:459-471.
12. Hourd P., Ginty P., Chandra A., Williams D.J. Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy 2014, 16:1033-1047.
13. Brindley D.A., Davie N.L., Culme-Seymour E.J., Mason C., Smith D.W., Rowley J.A. Peak serum: implications of serum supply for cell therapy manufacturing. Regener. Med. 2012, 7:7-13.
14. Hampson B., Rowley J., Venturi N. Manufacturing patient-specific cell therapy products. BioProcess Int. 2008, 6:60-72.
15. Wuchter P., Bieback K., Schrezenmeier H., Bornhauser M., Muller L.P., Bonig H., Wagner W., Meisel R., Pavel P., Tonn T., Lang P., Muller I., Renner M., Malcherek G., Saffrich R., Buss E.C., Horn P., Rojewski M., Schmitt A., Ho A.D., Sanzenbacher R., Schmitt M. Standardization of good manufacturing practice-compliant production of bone marrow-derived human mesenchymal stromal cells for immunotherapeutic applications. Cytotherapy 2014.
16. Williams D.J., Thomas R.J., Hourd P.C., Chandra A., Ratcliffe E., Liu Y., Rayment E.A., Archer J.R. Precision manufacturing for clinical-quality regenerative medicines. Philos. Trans. Ser. A Math. Phys. Eng. Sci. 2012, 370:3924-3949.
17. Carmen J., Burger S.R., McCaman M., Rowley J.A. Developing assays to address identity, potency, purity and safety: cell characterization in cell therapy process development. Regener. Med. 2012, 7:85-100.
18. Dominici M., Le Blanc K., Mueller I., Slaper-Cortenbach I., Marini F., Krause D., Deans R., Keating A., Prockop D., Horwitz E. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy 2006, 8:315-317.
19. Siddappa R., Licht R., van Blitterswijk C., de Boer J. Donor variation and loss of multipotency during in vitro expansion of human mesenchymal stem cells for bone tissue engineering. J. Orthop. Res. 2007, 25:1029-1041.
20. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363:1439-1441.
21. Le Blanc K., Frassoni F., Ball L., Locatelli F., Roelofs H., Lewis I., Lanino E., Sundberg B., Bernardo M.E., Remberger M., Dini G., Egeler R.M., Bacigalupo A., Fibbe W., Ringden O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371:1579-1586.
22. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., Cantos C., Jorgensen C., Noel D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells (Dayton Ohio) 2007, 25:2025-2032.
23. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103:4619-4621.
24. Siegel G., Kluba T., Hermanutz-Klein K., Bieback H., Schäfer R. Phenotype, donor age and gender affect function of human bone marrow-derived mesenchymal stromal cells. BMC Med. 2013, 11:1-20.
25. Galipeau J. The mesenchymal stromal cells dilemma-does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?. Cytotherapy 2015, 15:2-8.
26. U.S.D.o.H.a.H. Services, Guidance for industry: PAT-a framework for innovative pharmaceutical development, manufacturing and quality assurance, Food and Drug Administration (2004). http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm070305.pdf.
27. Rathore A.S., Kapoor G., Flickinger M.C. Process Analytical Technology: Strategies for Biopharmaceuticals, Encyclopedia of Industrial Biotechnology 2009, John Wiley & Sons Inc.
28. Cierpka K., Elseberg C.L., Niss K., Kassem M., Salzig D., Czermak P. hMSC production in disposable bioreactors with regards to GMP and PAT. Chem. Ing. Tech. 2013, 85:67-75.